Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).

Higginson IJ, Wilcock A, Johnson MJ, Bajwah S, Lovell N, Yi D, Hart SP, Crosby V, Poad H, Currow D, Best E, Brown S; BETTER-B Feasibility Trial Group.

Thorax. 2020 Jan 8. pii: thoraxjnl-2019-213879. doi: 10.1136/thoraxjnl-2019-213879. [Epub ahead of print]

2.

Holistic services for people with advanced disease and chronic or refractory breathlessness: a mixed-methods evidence synthesis.

Maddocks M, Brighton LJ, Farquhar M, Booth S, Miller S, Klass L, Tunnard I, Yi D, Gao W, Bajwah S, Man WDC, Higginson IJ.

Southampton (UK): NIHR Journals Library; 2019 Jun.

3.

To What Extent Do the NRS and CRQ Capture Change in Patients' Experience of Breathlessness in Advanced Disease? Findings From a Mixed-Methods Double-Blind Randomized Feasibility Trial.

Lovell N, Etkind SN, Bajwah S, Maddocks M, Higginson IJ.

J Pain Symptom Manage. 2019 Sep;58(3):369-381.e7. doi: 10.1016/j.jpainsymman.2019.06.004. Epub 2019 Jun 13.

4.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

5.

Service Delivery Models to Maximize Quality of Life for Older People at the End of Life: A Rapid Review.

Evans CJ, Ison L, Ellis-Smith C, Nicholson C, Costa A, Oluyase AO, Namisango E, Bone AE, Brighton LJ, Yi D, Combes S, Bajwah S, Gao W, Harding R, Ong P, Higginson IJ, Maddocks M.

Milbank Q. 2019 Mar;97(1):113-175. doi: 10.1111/1468-0009.12373. Review.

PMID:
30883956
6.

Recommendations for services for people living with chronic breathlessness in advanced disease: Results of a transparent expert consultation.

Brighton LJ, Tunnard I, Farquhar M, Booth S, Miller S, Yi D, Gao W, Bajwah S, Man WD, Reilly CC, Ogden M, Bailey S, Ewart C, Higginson IJ, Maddocks M.

Chron Respir Dis. 2019 Jan-Dec;16:1479973118816448. doi: 10.1177/1479973118816448.

7.

Predicting outcomes following holistic breathlessness services: A pooled analysis of individual patient data.

Brighton LJ, Gao W, Farquhar M, Booth S, Bajwah S, Man WD, Reilly CC, Yi D, Higginson IJ, Maddocks M.

Palliat Med. 2019 Apr;33(4):462-466. doi: 10.1177/0269216319830299. Epub 2019 Feb 15.

8.

Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential.

Lovell N, Wilcock A, Bajwah S, Etkind SN, Jolley CJ, Maddocks M, Higginson IJ.

Expert Rev Respir Med. 2019 Feb;13(2):173-180. doi: 10.1080/17476348.2019.1563486. Epub 2018 Dec 30. Review.

PMID:
30596298
9.

Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis.

Brighton LJ, Miller S, Farquhar M, Booth S, Yi D, Gao W, Bajwah S, Man WD, Higginson IJ, Maddocks M.

Thorax. 2019 Mar;74(3):270-281. doi: 10.1136/thoraxjnl-2018-211589. Epub 2018 Nov 29.

10.

Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study.

Bajwah S, Davies JM, Tanash H, Currow DC, Oluyase AO, Ekström M.

Eur Respir J. 2018 Dec 6;52(6). pii: 1801278. doi: 10.1183/13993003.01278-2018. Print 2018 Dec.

PMID:
30309973
11.

Control and Context Are Central for People With Advanced Illness Experiencing Breathlessness: A Systematic Review and Thematic Synthesis.

Lovell N, Etkind SN, Bajwah S, Maddocks M, Higginson IJ.

J Pain Symptom Manage. 2019 Jan;57(1):140-155.e2. doi: 10.1016/j.jpainsymman.2018.09.021. Epub 2018 Oct 4.

12.

Use of mirtazapine in patients with chronic breathlessness: A case series.

Lovell N, Bajwah S, Maddocks M, Wilcock A, Higginson IJ.

Palliat Med. 2018 Oct;32(9):1518-1521. doi: 10.1177/0269216318787450. Epub 2018 Jul 20.

PMID:
30028237
13.

Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review.

Carvajalino S, Reigada C, Johnson MJ, Dzingina M, Bajwah S.

BMC Pulm Med. 2018 May 22;18(1):78. doi: 10.1186/s12890-018-0651-3.

14.

Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease.

Johnson MJ, Jamali A, Ross J, Fairhurst C, Boland J, Reigada C, Hart SP, Grande G, Currow DC, Wells AU, Bajwah S, Papadopoulos T, Bland JM, Yorke J.

Thorax. 2018 Sep;73(9):880-883. doi: 10.1136/thoraxjnl-2017-210911. Epub 2017 Nov 17.

15.

Palliative care in interstitial lung disease: living well.

Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, Swigris J, Udwadia Z, Wells A, Wijsenbeek M.

Lancet Respir Med. 2017 Dec;5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. Epub 2017 Oct 13. Review.

16.

Palliative care and interstitial lung disease.

Bajwah S, Yorke J.

Curr Opin Support Palliat Care. 2017 Sep;11(3):141-146. doi: 10.1097/SPC.0000000000000285. Review.

PMID:
28661900
17.

One evidence base; three stories: do opioids relieve chronic breathlessness?

Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ.

Thorax. 2018 Jan;73(1):88-90. doi: 10.1136/thoraxjnl-2016-209868. Epub 2017 Apr 4.

PMID:
28377491
18.

Incident opioid drug use and adverse respiratory outcomes among older adults with COPD.

Ekström M, Bajwah S, Johnson MJ.

Eur Respir J. 2017 Mar 8;49(3). pii: 1602311. doi: 10.1183/13993003.02311-2016. Print 2017 Mar. No abstract available.

19.

Implementation of the Needs Assessment Tool for patients with interstitial lung disease (NAT:ILD): facilitators and barriers.

Reigada C, Papadopoulos A, Boland JW, Yorke J, Ross J, Currow DC, Hart S, Bajwah S, Grande G, Wells A, Johnson MJ.

Thorax. 2017 Nov;72(11):1049-1051. doi: 10.1136/thoraxjnl-2016-209768. Epub 2017 Feb 20.

20.

Which patients with advanced respiratory disease die in hospital? A 14-year population-based study of trends and associated factors.

Higginson IJ, Reilly CC, Bajwah S, Maddocks M, Costantini M, Gao W; GUIDE_Care project.

BMC Med. 2017 Feb 1;15(1):19. doi: 10.1186/s12916-016-0776-2.

21.

The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease.

Boland JW, Reigada C, Yorke J, Hart SP, Bajwah S, Ross J, Wells A, Papadopoulos A, Currow DC, Grande G, Macleod U, Johnson MJ.

J Palliat Med. 2016 May;19(5):549-55. doi: 10.1089/jpm.2015.0355. Epub 2016 Feb 3.

22.

Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention.

Bajwah S, Ross JR, Wells AU, Mohammed K, Oyebode C, Birring SS, Patel AS, Koffman J, Higginson IJ, Riley J.

Thorax. 2015 Sep;70(9):830-9. doi: 10.1136/thoraxjnl-2014-206583. Epub 2015 Jun 23.

PMID:
26103995
23.

Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease.

Patel AS, Siegert RJ, Bajwah S, Brignall K, Gosker HR, Moxham J, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

J Clin Epidemiol. 2015 Sep;68(9):1019-27. doi: 10.1016/j.jclinepi.2015.03.021. Epub 2015 Apr 10.

PMID:
26004514
24.

'I wish I knew more ...' the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals.

Bajwah S, Koffman J, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J.

BMJ Support Palliat Care. 2013 Mar;3(1):84-90. doi: 10.1136/bmjspcare-2012-000263. Epub 2012 Sep 28.

PMID:
24644332
25.

The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals.

Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Riley J, Koffman J.

Palliat Med. 2013 Oct;27(9):869-76. doi: 10.1177/0269216313497226. Epub 2013 Jul 24.

PMID:
23885010
26.

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

Patel AS, Siegert RJ, Keir GJ, Bajwah S, Barker RD, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

Respir Med. 2013 Sep;107(9):1438-43. doi: 10.1016/j.rmed.2013.06.009. Epub 2013 Jul 16.

27.

Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.

Bajwah S, Ross JR, Peacock JL, Higginson IJ, Wells AU, Patel AS, Koffman J, Riley J.

Thorax. 2013 Sep;68(9):867-79. doi: 10.1136/thoraxjnl-2012-202040. Epub 2012 Dec 1. Review.

PMID:
23204065
28.

Specialist palliative care is more than drugs: a retrospective study of ILD patients.

Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, Riley J.

Lung. 2012 Apr;190(2):215-20. doi: 10.1007/s00408-011-9355-7. Epub 2012 Jan 5.

PMID:
22218887
29.

General practitioners' use and experiences of palliative care services: a survey in south east England.

Bajwah S, Higginson IJ.

BMC Palliat Care. 2008 Nov 5;7:18. doi: 10.1186/1472-684X-7-18.

30.

Management of phenytoin toxicity in palliative care.

Bajwah S.

Palliat Med. 2007 Jan;21(1):63. No abstract available.

PMID:
17169967

Supplemental Content

Loading ...
Support Center